PRTX-100-202 Open-Label, Dose Escalation Study in Adult Patients With ITP

Stopped Enough data has been collected to allow analysis of safety profile and risk-benefit.

Conditions

• Immune Thrombocytopenia

Interventions

• DRUG: PRTX-100

Sponsor

Protalex, Inc.